Transgenic cell technologies play an important role in the elucidation of disease mechanisms, the development of new medical therapies based on these mechanisms and more specifically in the production of recombinant proteins. In particular, genome modifications have been made possible at the cellular level after the CRISPR-Cas9 system was demonstrated. In the future, it is predicted that CRISPR-Cas9 genome editing methods will be used in the elucidation and treatment of many diseases, especially cancer treatment.
In addition, the production of normal (wild-type) and mutant recombinant proteins with conventional recombinant protein production methods allows for the elucidation of disease mechanisms and the creation of a rational background for drug candidate molecules that can be developed against these diseases.
In addition, there is an increasing need for DNA methylation kits that can be used for forensic epigenetic studies and the source of biological fluid and tissue samples found at the crime scene (blood, saliva, seminal fluid, menstrual blood, etc.), differentiation of identical twins from each other, and determination of the age of the person to whom the biological sample (blood, saliva, seminal fluid, etc.) belongs.
Today, the term epigenetics is used precisely to describe changes in gene expression that are inherited independently of the DNA sequence of the organism. To date, it is also known that epigenetic changes play important roles in critical vital processes such as the normal development and metamorphosis of cells. Examples include X chromosome activation in female mammals and silencing of mating-type loci in yeast. However, epigenetic changes remain open to interaction throughout the lifespan and are therefore influenced by environmental factors and the aging process. Therefore, there is growing scientific evidence suggesting that the mechanisms of cancer and a number of other diseases can be linked to changes in epigenetic mechanisms. Against this scientific background, investigating epigenetic mechanisms using transgenic cell technologies and developing drug candidate molecules based on these mechanisms will contribute to the position of our country in the world in this field and will be instrumental in the development of national drugs. Therefore, the establishment of T.C ÜSKÜDAR TRANSGENIC CELL TECHNOLOGIES AND EPIGENETICS APPLICATION AND RESEARCH CENTER is also planned to contribute to our country's efforts to develop epigenetic-based national drugs.